What changed between these versions
A complete substitute amendment, v2 largely retains the core policy objectives of v1 to schedule xylazine and regulate its use. While maintaining most provisions, v2 introduces a new "Control Report" requirement for the Attorney General and Secretary of Health and Human Services, and makes minor structural and definitional adjustments. v2 is effectively a different bill from v1 due to the comprehensive replacement of its text.
Overview
The changes between v1 and v2 are extensive, constituting a complete substitute of the original bill text. · The overall direction is a refinement and expansion of oversight mechanisms, particularly regarding initial assessments and reporting, rather than a fundamental shift in policy.
v2 is a complete substitute amendment that replaces the entirety of v1's text after the enacting clause. The most significant change is the addition of a new "Control Report" in Section 7, requiring an expedited assessment of xylazine's scheduling factors by the Attorney General and Secretary of Health and Human Services within 30 days of enactment. While the bill's fundamental purpose of scheduling xylazine as a Schedule III controlled substance and regulating its legitimate uses remains, v2 also includes minor updates to definitions, clarifies certain procedural aspects like ARCOS tracking language, and updates references from "title" to "Act" to reflect the comprehensive nature of the substitute.
Major additions
This new subsection mandates the Attorney General, acting through the DEA Administrator and in coordination with the Secretary of Health and Human Services, to submit a "Control Report" to Congress within 30 days of enactment. This report must include an assessment of factors for xylazine's control under the Controlled Substances Act, a scientific and medical evaluation, and a law enforcement and abuse evaluation. It also requires the inclusion of a scientific and medical evaluation submitted to the Attorney General by December 31, 2025, and public publication of the report on agency websites.
This addition significantly accelerates and expands the initial assessment and reporting requirements for xylazine's scheduling. It introduces an urgent, comprehensive review process with public transparency, which was not present in v1's reporting structure, thereby providing Congress with critical information much sooner.
Modifications
This modification clarifies the term "practitioner" for the purposes of the Act, which is relevant for legitimate xylazine use, and updates the specific statutory reference for xylazine within the Controlled Substances Act, ensuring proper legal referencing for its control.
Before
v1 defined the term "xylazine" by adding paragraph (60) to Section 102 of the Controlled Substances Act.
After
v2 defines the term "practitioner" in Section 2(a)(1) of the Act and defines "xylazine" by adding paragraph (61) to Section 102 of the Controlled Substances Act.
This change clarifies that the non-registration requirement for ultimate users applies to the entire enacted bill, ensuring consistent legal interpretation and application across the new legislative text.
Before
v1 stated that nothing in "this title" or its amendments should be construed to require ultimate user registration for xylazine.
After
v2 states that nothing in "this Act" or its amendments should be construed to require ultimate user registration for xylazine.
This modification ensures that ARCOS tracking explicitly includes both gamma hydroxybutyric acid *and* xylazine, making the tracking more comprehensive and mandatory for xylazine alongside other scheduled substances, thereby enhancing monitoring of its distribution.
Before
v1 amended Section 307(i)(6) of the Controlled Substances Act by inserting "or xylazine" after "gamma hydroxybutyric acid" for ARCOS tracking purposes.
After
v2 amends Section 307(i)(6) of the Controlled Substances Act by inserting "and xylazine" after "gamma hydroxybutyric acid" for ARCOS tracking purposes.
This change clarifies that the Sentencing Commission's review should consider the entire scope of the enacted bill, ensuring consistency with the new legislative framework and comprehensive application of penalties for xylazine offenses.
Before
v1 directed the United States Sentencing Commission to review and amend sentencing guidelines for xylazine offenses consistent with amendments made by "this title".
After
v2 directs the United States Sentencing Commission to review and amend sentencing guidelines for xylazine offenses consistent with amendments made by "this Act".
This modification significantly accelerates the initial review process by requiring a comprehensive assessment of xylazine's scheduling factors within 30 days of enactment, including scientific, medical, and law enforcement evaluations, with public transparency. This provides Congress with crucial information much earlier than originally planned in v1.
Before
v1 included two reporting requirements: an "Initial Report" due 18 months after enactment and an "Additional Report" due 4 years after enactment.
After
v2 adds a new "Control Report" due 30 days after enactment, then renumbers v1's "Initial Report" to (b) and "Additional Report" to (c). The content of the renumbered reports remains largely the same.
Scope
Complete substitute — Changes are scattered throughout the bill, affecting definitions, procedural exemptions, tracking mechanisms, sentencing guidelines, and significantly expanding reporting requirements. — While the core policy direction of scheduling xylazine as a controlled substance remains consistent, v2 introduces a new, expedited reporting and assessment mechanism, indicating a more urgent and structured approach to its control and monitoring. — The changes interact with existing provisions of the Controlled Substances Act by modifying definitions, adding to schedules, and altering reporting requirements. The consistent change from "title" to "Act" in several places ensures that the scope of the substitute bill is uniformly applied to all related statutory references.
Impact analysis
Drug Enforcement Administration (DEA) and Department of Health and Human Services (HHS)
Increased responsibility and transparency in the initial assessment of xylazine's scheduling.
Required to produce an expedited "Control Report" within 30 days of enactment, including scientific, medical, and law enforcement evaluations, and to publish it publicly on their websites.
Manufacturers of xylazine
Continued clarity and consistent timelines for compliance.
No change in the transition periods for security standards, labeling, or practitioner registration requirements, which remain consistent with v1's provisions.
United States Sentencing Commission
Clarified scope of review for sentencing guidelines related to xylazine offenses.
Directed to review and amend sentencing guidelines for xylazine offenses, consistent with the amendments made by "this Act" (v2) rather than "this title" (v1).